Analyzing Treace Medical Concepts (NASDAQ:TMCI) & Microbot Medical (NASDAQ:MBOT)

Treace Medical Concepts (NASDAQ:TMCI) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Earnings & Valuation

This table compares Treace Medical Concepts and Microbot Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$198.53 million	1.63	-$49.53 million	($0.88)	-5.92
Microbot Medical	N/A	N/A	-$10.74 million	($0.89)	-1.05

Microbot Medical has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Treace Medical Concepts and Microbot Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-32.08%	-49.53%	-26.50%
Microbot Medical	N/A	-173.35%	-130.38%

Volatility & Risk

Treace Medical Concepts has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.

Institutional and Insider Ownership

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 24.4% of Treace Medical Concepts shares are owned by company insiders. Comparatively, 10.6% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Treace Medical Concepts and Microbot Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	0	6	0	0	2.00
Microbot Medical	0	0	1	0	3.00

Treace Medical Concepts currently has a consensus price target of $7.30, suggesting a potential upside of 40.12%. Microbot Medical has a consensus price target of $7.00, suggesting a potential upside of 646.99%. Given Microbot Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Microbot Medical is more favorable than Treace Medical Concepts.

Summary

Microbot Medical beats Treace Medical Concepts on 7 of the 13 factors compared between the two stocks.

About Treace Medical Concepts

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.